Chinese Firms Targeted U.S. Pharma Assets Across the Entire Value Chain

Selected acquisitions in generics, biologics, R&D tools, and genomics, 2008–20

Table of selected Chinese acquisitions of pharmaceutical and life sciences companies from 2008 to 2020, organized by category — generics, monoclonals and biologics, R&D tools and critical equipment, and genomics — showing acquirer, deal size, and strategic implications.

(Please use a modern browser to see the interactive version of this visualization)

Sources: PRNewswire, SEC filings, Fosun Pharma, Fierce Pharma, PRWeb, BioSpace, Pharmaron. Deal sizes reflect announced terms; some subject to adjustments.